+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Adenosine A2B receptor antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Adenosine A2B receptor antagonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
From
Adenosine receptor antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Adenosine receptor antagonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 80 Pages
  • Global
From
Somatostatin Receptor Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Somatostatin Receptor Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Glucokinase Activators - Pipeline Insight, 2024 - Product Thumbnail Image

Glucokinase Activators - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Insulin Like Growth Factor 1 (IGF-1) Activators - Pipeline Insight, 2024 - Product Thumbnail Image

Insulin Like Growth Factor 1 (IGF-1) Activators - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Parathyroid Hormone Receptor Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Parathyroid Hormone Receptor Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Epidermal growth factor receptor antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Epidermal growth factor receptor antagonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Thyroid hormone receptor agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Thyroid hormone receptor agonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Amyloid beta-protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Amyloid beta-protein inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
MTORC1 protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

MTORC1 protein inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
SMO protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

SMO protein inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Exportin-1 protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Exportin-1 protein inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
MPYS protein stimulants - Pipeline Insight, 2024 - Product Thumbnail Image

MPYS protein stimulants - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 80 Pages
  • Global
From
PRMT5 protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

PRMT5 protein inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
DUX4 protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

DUX4 protein inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
WEE1 protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

WEE1 protein inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
MPYS protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

MPYS protein inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
From
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more